Valar Labs

These entrepreneurs and researchers are taking on some of healthcare’s biggest challenges, from developing new drugs to building new devices to expanding access to care. #ForbesUnder30 trib.al/BUIVaEE

Excited to share our @valarlabs publication in @EUplatinum validating Vesta Risk Stratify computational histology AI biomarkers to predict recurrence and progression in High Grade Ta Bladder Cancer. (1/5) Publication: authors.elsevier.com/c/1lFoD14kpm0h…

Comprehensive breakdown of our recent @EurUrolOncol publication

Our recent publication in @EurUrolOncol demonstrates - for the first time -that an AI-powered histologic biomarker (CHAI) can predict response to intravesical BCG vs. gemcitabine/docetaxel in high-grade NMIBC. A critical step forward in precision intravesical therapy.…

An #ArtificialIntelligence-powered predictive biomarker for response to intravesical BCG versus gemcitabine-docetaxel for high-grade #NMIBC. Presentation by @VigneshPackiam @RutgersCancer. #AUA25 written coverage by @RKSayyid @USC > bit.ly/4jQSrbg @AmerUrological

🌟AI meets #BladderCancer care! This new study explores the CHAI biomarker, an AI-powered histologic tool that: 🔸️Predicts poor responders to BCG 🔸️ Is not associated with poor outcomes on Gemcitabine/Docetaxel 🔸️May help personalize therapy in high-grade NMIBC A step…

Excited to share this paper which has been many years in the making! This is the first publication of a predictive (AI-histology based) biomarker to guide rational use of BCG vs Gem/Doce for newly diagnosed HG NMIBC pubmed.ncbi.nlm.nih.gov/40287344/ Curves say it all 👇🏾

30 Under 30 Healthcare 2025: Advancing AI, Delivering Care And Creating New Therapies #ForbesUnder30 trib.al/o7L5YAz

AI Powered Model to Predict Response to Intravesical BCG Versus Gem-Doce for HR NMIBC @VigneshPackiam @valarlabs @urotoday #SUO24 🎯 CHAI biomarker +ve: Predictive of ⬆️ HG-RFS in pts treated with Gem-Doce vs BCG ⚡️First AI-based histologic biomarker to predict clinical…

It's been a privilege to collaborate with @ylotan @UroDocAsh on our international 12 center clinical validation study predicting outcomes and response to BCG using #CHAI biomarkers. We are excited for the impact #Vesta will have for bladder cancer patient care. @urotoday

Leveraging AI biomarkers to navigate the evolving landscape of #BladderCancer treatment @SWilliams_MD @UTMBUrology joins @zklaassen_md @GACancerCenter to discuss this innovative AI biomarker for #NMIBC > bit.ly/44JLkLj @valarlabs

We @a16z are thrilled to announce our Series A investment in @valarlabs, which is building AI tools to assist oncologists in cancer treatment decisions. There are roughly 2 million new cancer diagnoses annually in the US alone. Each diagnosis involves a biopsy of the patient's…